InnoCare is developing a portfolio of novel drugs for cancer and autoimmune diseases, using a combination of in-licensing and internal research.
February 9, 2018 -- Beijing InnoCare Pharma raised $55 million in a funding round led by Vivo Capital and joined by CCB Capital. InnoCare is developing a portfolio of novel drugs for cancer and autoimmune diseases, using a combination of in-licensing and internal research. The company hopes its candidates, which target both China and global markets, will prove to be either first-in-class or best-in-class. InnoCare expects to release “landmark” clinical trial results this year.
